Quinolones in Salmonella typhi infection

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Quinolones exhibit potent in vitro activity against enteric bacteria like Salmonella.
• Limitations of current antityphoid agents necessitate exploring new therapeutic options.
• Salmonella typhi infections, including typhoid fever and chronic carriage, pose significant public health challenges.

Purpose of the Study:

• To evaluate the efficacy of quinolones in treating Salmonella typhi infections.
• To assess quinolones as a therapeutic option for typhoid fever and chronic intestinal carriage.
• To determine if quinolones can overcome resistance to conventional antityphoid drugs.

Main Methods:

• Open uncontrolled trials involving over 200 patients with culture-proven typhoid fever.
• Comparative clinical trials assessing quinolones against standard antityphoid therapies.
• Studies investigating the effectiveness of norfloxacin and ciprofloxacin in eliminating S. typhi in chronic carriers.

Main Results:

• Norfloxacin, ciprofloxacin, ofloxacin, and pefloxacin were successfully used in uncontrolled trials for typhoid fever.
• Comparative trials showed quinolones (ciprofloxacin, ofloxacin, pefloxacin, fleroxacin) were equivalent or superior to standard treatments.
• Norfloxacin and ciprofloxacin effectively eliminated S. typhi intestinal excretion in chronic carriers.

Conclusions:

• Quinolones demonstrate significant efficacy in treating both typhoid fever and chronic S. typhi intestinal carriage.
• Increasing resistance to traditional antityphoid drugs highlights the importance of quinolone therapy.
• Quinolones may emerge as the preferred treatment for S. typhi infections due to their effectiveness and broad activity.